ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.
Strong growth in instrument revenue, driven by sales of the Sequel II system, was tempered by decreased consumable revenue as customers transitioned to the new platform.
Personal Genomics alleged that PacBio tried to sublicense the patent-in-suit in the years prior to its launch of the Sequel sequencing platform.
The patent, EP3170904, "Compositions and methods for nucleic acid sequencing," is the second PacBio patent revoked by the EPO this year.
The company recognized total first quarter revenues of $16.4 million and a net loss of $30.3 million.
In a retrospective analysis, UK researchers found that long-read sequencing of HLA genes in stem cell transplantation donors and recipients led to better outcomes.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
PacBio agreed to pay attorneys' fees to settle lawsuits brought against it by investors regarding Illumina's acquisition.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.